A Prototype Recombinant-Protein Based <i>Chlamydia pecorum</i> Vaccine Results in Reduced Chlamydial Burden and Less Clinical Disease in Free-Ranging Koalas (<i>Phascolarctos cinereus</i>)

<div><p>Diseases associated with <i>Chlamydia pecorum</i> infection are a major cause of decline in koala populations in Australia. While koalas in care can generally be treated, a vaccine is considered the only option to effectively reduce the threat of infection and disease at the population level. In the current study, we vaccinated 30 free-ranging koalas with a prototype <i>Chlamydia pecorum</i> vaccine consisting of a recombinant chlamydial MOMP adjuvanted with an immune stimulating complex. An additional cohort of 30 animals did not receive any vaccine and acted as comparison controls. Animals accepted into this study were either uninfected (<i>Chlamydia</i> PCR negative) at time of initial vaccination, or infected (<i>C</i>. <i>pecorum</i> positive) at either urogenital (UGT) and/or ocular sites (Oc), but with no clinical signs of chlamydial disease. All koalas were vaccinated / sampled and then re-released into their natural habitat before re-capturing and re-sampling at 6 and 12 months. All vaccinated koalas produced a strong immune response to the vaccine, as indicated by high titres of specific plasma antibodies. The incidence of new infections in vaccinated koalas over the 12-month period post-vaccination was slightly less than koalas in the control group, however, this was not statistically significant. Importantly though, the vaccine was able to significantly reduce the infectious load in animals that were <i>Chlamydia</i> positive at the time of vaccination. This effect was evident at both the Oc and UGT sites and was stronger at 6 months than at 12 months post-vaccination. Finally, the vaccine was also able to reduce the number of animals that progressed to disease during the 12-month period. While the sample sizes were small (statistically speaking), results were nonetheless striking. This study highlights the potential for successful development of a <i>Chlamydia</i> vaccine for koalas in a wild setting.</p>